Methoxylation of Desazadesferrithiocin Analogues
J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 8 1477
(12) Halliwell, B. Free Radicals and Antioxidants: A Personal View.
Nutr. Rev. 1994, 52, 253-265.
(37) Anderegg, G.; Ra¨ber, M. Metal Complex Formation of a New
Siderophore Desferrithiocin and of Three Related Ligands. J .
Chem. Soc., Chem. Commun. 1990, 1194-1196.
(38) Bergeron, R. J .; Wiegand, J .; Dionis, J . B.; Egli-Karmakka, M.;
Frei, J .; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desfer-
rithiocin and Its Synthetic Analogues as Orally Effective Iron
Chelators. J . Med. Chem. 1991, 34, 2072-2078.
(39) Bergeron, R. J .; Streiff, R. R.; Wiegand, J .; Vinson, J . R. T.;
Luchetta, G.; Evans, K. M.; Peter, H.; J enny, H.-B. A Compara-
tive Evaluation of Iron Clearance Models. Ann. N. Y. Acad. Sci.
1990, 612, 378-393.
(13) Koppenol, W. Kinetics and Mechanism of the Fenton Reaction:
Implications for Iron Toxicity. In Iron Chelators: New Develop-
ment Strategies; Badman, D. G., Bergeron, R. J ., Brittenham,
G. M., Eds.; Saratoga: Ponte Vedra Beach, FL, 2000; pp 3-10.
(14) Babbs, C. F. Oxygen Radicals in Ulcerative Colitis. Free Radical
Biol. Med. 1992, 13, 169-181.
(15) Dean, R. T.; Nicholson, P. The Action of Nine Chelators on Iron-
Dependent Radical Damage. Free Radical Res. 1994, 20, 83-
101.
(40) Bergeron, R. J .; Streiff, R. R.; Creary, E. A.; Daniels, R. D., J r.;
King, W.; Luchetta, G.; Wiegand, J .; Moerker, T.; Peter, H. H.
A Comparative Study of the Iron-Clearing Properties of Desfer-
rithiocin Analogues with Desferrioxamine B in a Cebus Monkey
Model. Blood 1993, 81, 2166-2173.
(16) Raymond, K. N.; Carrano, C. J . Coordination Chemistry and
Microbial Iron Transport. Acc. Chem. Res. 1979, 12, 183-190.
(17) Martell, A. E.; Motekaitis, R. J .; Sun, Y.; Clarke, E. T. Ligand
Design of Chelating Agents Effective in the Coordination of Fe-
(III) and for the Removal of Iron in Cases of Iron Overload. In
The Development of Iron Chelators for Clinical Use; Bergeron,
R. J ., Brittenham, G. M., Eds.; CRC: Boca Raton, 1994; pp 329-
351.
(41) Bergeron, R. J .; Liu, C. Z.; McManis, J . S.; Xia, M. X. B.; Algee,
S. E.; Wiegand, J . The Desferrithiocin Pharmacophore. J . Med.
Chem. 1994, 37, 1411-1417.
(42) Bergeron, R. J .; Wiegand, J .; Wollenweber, M.; McManis, J . S.;
Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological
Evaluation of Naphthyldesferrithiocin Iron Chelators. J . Med.
Chem. 1996, 39, 1575-1581.
(43) Bergeron, R. J .; Wiegand, J .; Weimar, W. R.; Vinson, J . R. T.;
Bussenius, J .; Yao, G. W.; McManis, J . S. Desazadesmethyldes-
ferrithiocin Analogues as Orally Effective Iron Chelators. J . Med.
Chem. 1999, 42, 95-108.
(44) Bergeron, R. J .; Wiegand, J .; McManis, J . S.; McCosar, B. H.;
Weimar, W. R.; Brittenham, G. M.; Smith, R. E. Effects of C-4
Stereochemistry and C-4′ Hydroxylation on the Iron Clearing
Efficiency and Toxicity of Desferrithiocin Analogues. J . Med.
Chem. 1999, 42, 2432-2440.
(45) Karmarkar, S. N.; Kelkar, S. L.; Wadia, M. S. A Simple Unusual
One-Step Conversion of Aromatic Aldehydes into Nitriles.
Synthesis 1985, 510-512.
(46) Kaufmann, R. J .; Adams, R. Production of Imido Thiol Esters
by the Condensation of Thiocyanates with Resorcinol or Phlo-
roglucinol. J . Am. Chem. Soc. 1923, 45, 1744-1752.
(47) Wolfe, L. C.; Nicolosi, R. J .; Renaud, M. M.; Finger, J .; Hegsted,
M.; Peter, H.; Nathan, D. G. A Non-Human Primate Model for
the Study of Oral Iron Chelators. Br. J . Haematol. 1989, 72,
456-461.
(48) Cragg, L.; Hebbel, R. P.; Miller, W.; Solovey, A.; Selby, S.;
Enright, H. The Iron Chelator L1 Potentiates Oxidative DNA
Damage in Iron-Loaded Liver Cells. Blood 1998, 92, 632-638.
(49) Bergeron, R. J .; Wiegand, J .; Weimar, W. R.; Nguyen, J . N.;
Sninsky, C. A. Prevention of Acetic Acid-Induced Colitis by
Desferrithiocin Analogs in a Rat Model. Dig. Dis. Sci. 2003, 48,
399-407.
(50) Bergeron, R. J .; Huang, G.; Weimar, W. R.; Smith, R. E.;
Wiegand, J .; McManis, J . S. Desferrithiocin Analogue-Based
Hexacoordinate Iron(III) Chelators. J . Med. Chem. 2003, 46, 16-
24.
(51) Samuni, A. M.; Afeworki, M.; Stein, W.; Yordanov, A. T.; DeGraff,
W.; Krishna, M. C.; Mitchell, J . B.; Brechbiel, M. W. Multifunc-
tional Antioxidant Activity of HBED Iron Chelator. Free Radical
Biol. Med. 2001, 30, 170-177.
(52) Denicola, A.; Souza, J . M.; Gatti, R. M.; Augusto, O.; Radi, R.
Desferrioxamine Inhibition of the Hydroxyl Radical-Like Reac-
tivity of Peroxynitrite: Role of the Hydroxamic Groups. Free
Radical Biol. Med. 1995, 19, 11-19.
(53) Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.;
Rice-Evans, C. Antioxidant Activity Applying an Improved ABTS
Radical Cation Decolorization Assay. Free Radical Biol. Med.
1999, 26, 1231-1237.
(54) Gomori, G. Preparation of Buffers for Use in Enzyme Studies.
Methods Enzymol. 1955, 1, 138-146.
(55) Crooks, H. M. Penicillamine, Its Analogs and Homologs. In The
Chemistry of Penicillin; Clarke, H. T., J ohnson, J . R., Robinson,
R., Eds.; Princeton University Press: Princeton, NJ , 1949; pp
455-472.
(56) Bergeron, R. J .; Streiff, R. R.; Wiegand, J .; Luchetta, G.; Creary,
E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties
of 1,2-Dimethyl-3-hydroxypyrid-4-one, 1,2-Diethyl-3-hydroxypy-
rid-4-one, and Deferoxamine. Blood 1992, 79, 1882-1890.
(57) Wood, J . K.; Milner, P. F.; Pathak, U. N. The Metabolism of Iron-
(18) Anderegg, G.; L’Eplattenier, F.; Schwarzenbach, G. Hydroxamate
Complexes. II. Application of the pH Methodology. Helv. Chim.
Acta 1963, 46, 1400-1408.
(19) Harris, W. R.; Carrano, C. J .; Cooper, S. R.; Sofen, S. R.; Avdeef,
A. E.; McArdle, J . V.; Raymond, K. N. Coordination Chemistry
of Microbial Iron Transport Compounds. XIX. Stability Con-
stants and Electrochemical Behavior of Ferric Enterobactin and
Model Complexes. J . Am. Chem. Soc. 1979, 101, 6097-6104.
(20) Neilands, J . B.; Peterson, T.; Leong, S. A. High Affinity Iron
Transport in Microorganisms. Iron (III) Coordination Com-
pounds of the Siderophores Agrobactin and Parabactin. In
Inorganic Chemistry in Biology and Medicine; Martell, A. E.,
Ed.; American Chemical Society: Washington, DC, 1980; pp
263-278.
(21) Harris, W. R.; Carrano, C. J .; Raymond, K. N. Spectrophoto-
metric Determination of the Proton-Dependent Stability Con-
stant of Ferric Enterobactin. J . Am. Chem. Soc. 1979, 101, 2213-
2214.
(22) Bickel, H.; Hall, G. E.; Keller-Schierlein, W.; Prelog, V.; Vischer,
E.; Wettstein, A. Metabolic Products of Actinomycetes. XXVII.
Constitutional Formula of Ferrioxamine B. Helv. Chim. Acta
1960, 43, 2129-2138.
(23) Olivieri, N. F.; Brittenham, G. M. Iron-Chelating Therapy and
the Treatment of Thalassemia. Blood 1997, 89, 739-761.
(24) Giardina, P. J .; Grady, R. W. Chelation Therapy in â-Thalas-
semia: An Optimistic Update. Semin. Hematol. 2001, 38, 360-
366.
(25) Pippard, M. J . Desferrioxamine-Induced Iron Excretion in
Humans. Bailliere’s Clin. Haematol. 1989, 2, 323-343.
(26) Whitten, C. F.; Gibson, G. W.; Good, M. H.; Goodwin, J . F.;
Brough, A. J . Studies in Acute Iron Poisoning. I. Desferrioxamine
in the Treatment of Acute Iron Poisoning: Clinical Observations,
Experimental Studies, and Theoretical Considerations. Pediat-
rics 1965, 36, 322-335.
(27) Athanasiou, A.; Shepp, M. A.; Necheles, T. F. Anaphylactic
Reaction to Desferrioxamine. Lancet 1977, 2, 616.
(28) Shalit, M.; Tedeschi, A.; Miadonna, A.; Levi-Schaffer, F. Desferal
(Desferrioxamine) - A Novel Activator of Tissue-Type Mast
Cells. J . Allergy Clin. Immunol. 1991, 88, 854-860.
(29) Bousquet, J .; Navarro, M.; Robert, G.; Aye, P.; Michel, F. B.
Rapid Desensitization for Desferrioxamine Anaphylactoid Reac-
tions. Lancet 1983, 2, 859-860.
(30) Miller, K. B.; Rosenwasser, L. J .; Bessette, J . A. M.; Beer, D. J .;
Rocklin, R. E. Rapid Desensitisation for Desferrioxamine Ana-
phylactic Reaction. Lancet 1981, 1, 1059.
(31) Olivieri, N. F.; Buncic, J . R.; Chew, E.; Gallant, T.; Harrison, R.
V.; Keenan, N.; Logan, W.; Mitchell, D.; Ricci, G.; Skarf, B.;
Taylor, M.; Freedman, M. H. Visual and Auditory Neurotoxicity
in Patients Receiving Subcutaneous Deferoxamine Infusions. N.
Engl. J . Med. 1986, 314, 869-873.
(32) Nouel, O.; Voisin, P. M.; Vaucel, J .; Dartois Hoguin, M.; Le Bris,
M. [Yersinia enterocolitica Septicemia Associated with Idiopathic
Hemochromatosis and Deferoxamine Therapy. A Case]. Presse
Med. 1991, 20, 1494-1496.
(33) Bentur, Y.; McGuigan, M.; Koren, G. Deferoxamine (Desferri-
oxamine). New Toxicities for an Old Drug. Drug Saf. 1991, 6,
37-46.
(34) Pippard, M. J .; J ackson, M. J .; Hoffman, K.; Petrou, M.; Modell,
C. B. Iron Chelation Using Subcutaneous Infusions of Diethylene
Triamine Penta-acetic Acid (DTPA). Scand. J . Haematol. 1986,
36, 466-472.
(35) Naegeli, H.-U.; Za¨hner, H. Metabolites of Microorganisms. Part
193. Ferrithiocin. Helv. Chim. Acta 1980, 63, 1400-1406.
(36) Hahn, F. E.; McMurry, T. J .; Hugi, A.; Raymond, K. N.
Coordination Chemistry of Microbial Iron Transport. 42. Struc-
tural and Spectroscopic Characterization of Diastereomeric Cr-
(III) and Co(III) Complexes of Desferriferrithiocin. J . Am. Chem.
Soc. 1990, 112, 1854-1860.
Dextran Given as
a Total-Dose Infusion to Iron Deficient
J amaican Subjects. Br. J . Haematol. 1968, 14, 119-129.
(58) Bergeron, R. J .; Wiegand, J .; Brittenham, G. M. HBED:
A
Potential Alternative to Deferoxamine for Iron-Chelating Therapy.
Blood 1998, 91, 1446-1452.
(59) Bergeron, R. J .; Wiegand, J .; Brittenham, G. M. HBED: The
Continuing Development of a Potential Alternative to Deferox-
amine for Iron-Chelating Therapy. Blood 1999, 93, 370-375.
(60) Sangster, J . Octanol-Water Partition Coefficients: Fundamentals
and Physical Chemistry; J ohn Wiley and Sons: West Sussex,
England, 1997.
J M020412D